Rubrik, Inc. (NYSE:RBRK – Get Free Report) major shareholder Barry Eggers sold 100,000 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $32.74, for a total transaction of $3,274,000.00. Following the transaction, the insider now owns 56,736 shares of the company’s stock, valued at $1,857,536.64. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Rubrik Trading Up 0.7 %
Shares of Rubrik stock opened at $33.59 on Wednesday. Rubrik, Inc. has a 52-week low of $28.34 and a 52-week high of $40.00. The business has a 50 day moving average price of $33.44.
Hedge Funds Weigh In On Rubrik
Hedge funds have recently modified their holdings of the company. Davidson Kempner Capital Management LP purchased a new stake in Rubrik in the 2nd quarter worth approximately $2,606,000. ARK Investment Management LLC bought a new stake in Rubrik in the second quarter valued at $6,043,000. EPIQ Capital Group LLC bought a new stake in Rubrik in the second quarter valued at $15,111,000. Octahedron Capital Management L.P. purchased a new position in Rubrik during the 2nd quarter valued at $4,936,000. Finally, Liberty Street Advisors Inc. bought a new position in Rubrik in the 2nd quarter worth $4,117,000.
Analysts Set New Price Targets
Rubrik Company Profile
Rubrik, Inc provides data security solutions to individuals and businesses worldwide. The company offers enterprise data protection, unstructured data protection, cloud data protection, and SaaS data protection solutions; data threat analytics; data security posture; and cyber recovery solutions. It serves financial, retail, trade, transportation, energy, industrial, healthcare and life science, education, technology, media, communications, and public sectors.
Read More
- Five stocks we like better than Rubrik
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Health Care Stocks Explained: Why You Might Want to Invest
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What Investors Need to Know to Beat the Market
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Rubrik Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubrik and related companies with MarketBeat.com's FREE daily email newsletter.